Last reviewed · How we verify
TACE with Drug Eluting Beads procedure
TACE with drug-eluting beads delivers chemotherapy directly to hepatocellular carcinoma tumors via arterial catheterization while blocking blood supply to the tumor.
TACE with drug-eluting beads delivers chemotherapy directly to hepatocellular carcinoma tumors via arterial catheterization while blocking blood supply to the tumor. Used for Hepatocellular carcinoma (HCC), unresectable or as bridge to transplantation.
At a glance
| Generic name | TACE with Drug Eluting Beads procedure |
|---|---|
| Also known as | DEB-TACE |
| Sponsor | Ain Shams University |
| Drug class | Interventional oncology procedure / chemoembolization |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This is a minimally invasive interventional procedure that combines transarterial chemoembolization (TACE) with drug-eluting beads (DEBs) that are loaded with chemotherapeutic agents. The beads are injected into the hepatic artery feeding the tumor, where they lodge in the tumor vasculature, releasing chemotherapy locally while simultaneously occluding blood flow to starve the tumor of oxygen and nutrients.
Approved indications
- Hepatocellular carcinoma (HCC), unresectable or as bridge to transplantation
Common side effects
- Post-embolization syndrome (fever, abdominal pain, nausea)
- Hepatic dysfunction/elevated liver enzymes
- Fatigue
- Vomiting
- Arterial dissection or perforation
- Hepatic abscess
Key clinical trials
- IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (PHASE2)
- CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
- DEB-TACE vs cTACE in HCC After TIPS (PHASE3)
- CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab (PHASE2)
- A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer (EARLY_PHASE1)
- Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads (PHASE1)
- DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases (PHASE3)
- The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TACE with Drug Eluting Beads procedure CI brief — competitive landscape report
- TACE with Drug Eluting Beads procedure updates RSS · CI watch RSS
- Ain Shams University portfolio CI